Navigation Links
Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial
Date:9/1/2010

were held across 90 centers in 7 countries.

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin has completed two Phase III clinical trials for the non-surgical treatment of retinal disorders. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (anti-Factor VIII), a long acting anti-coagulant in Phase II, and TB-403 (anti-PlGF) in Phase Ib/II for cancer in partnership with Roche.

ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

For further information please contact: ThromboGenics Dr. Steve Pakola, CMO Tel: +1(212)201-0920 steve.pakola@thrombogenics.com
'/>"/>

SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology
2. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
3. Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
4. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
5. SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
6. Xceed Meets HTX/CIHR Grant Milestone: Decreasing Sample-Prep Time From Days to Less Than Eight Hours
7. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
8. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
9. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
10. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
11. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... July 07, 2015 , ... CSM, a leading clinical trial supply company, today ... Morse has an extensive background in financial management and accounting, bringing over 20 years ... new role, Morse will oversee all financial areas of the company to both strengthen ...
(Date:7/6/2015)... USA, and CARDIFF, UK (PRWEB) , ... July ... ... in ophthalmology and other medical fields holds potential to reveal how blood flows ... and reduce stroke-induced damage to the brain. , A new article published in ...
(Date:7/6/2015)...  Approximately 1% of the population inherits a common ... individuals are three times more likely to develop angina, ... the nation,s leading medical journals by researchers from the ... Photo - http://photos.prnewswire.com/prnh/20150706/230685 The ... (also known as "sixth disease") and occasional seizures in ...
(Date:7/6/2015)... , June 29, 2015 ... has announced the addition of the "Biotechnology ... Biotechnology for the Non-Biotechnologist, ideal for ... theory, principles, techniques and potential of biotechnology. ... understand the basic theory, principles, techniques, and potential ...
Breaking Biology Technology:CSM Appoints Michael Morse as Vice President of Finance 2Reducing Stroke Damage May be Next Application for OCT Technology Now Widely Used in Eye and Vision Healthcare 2Reducing Stroke Damage May be Next Application for OCT Technology Now Widely Used in Eye and Vision Healthcare 3Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 3
... (Nasdaq: EXEL ) announced today that George A. ... present at,the 19th Annual Piper Jaffray Health Care Conference ... November 27, 2007., The presentation will be webcast ... Investors on the Exelixis website at, http://www.exelixis.com ., ...
... findings published in November 22 issue of Nature ... first system-wide gene-analysis of microbial community focused ... Nov. 21 Verenium,Corporation (Nasdaq: VRNM ), ... and a pioneer in the development of,high-performance specialty ...
... SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) announced today that ... which Mike Grey, president & chief,executive officer of SGX Pharmaceuticals, ... information is as follows:, -- 19th Annual Piper ... November 27, 2007 at 11:30 AM Eastern Standard Time at ...
Cached Biology Technology:Verenium Explores Bacterial Genes Inside Termite Guts to Understand How Wood is Broken Down and Converted to Energy 2Verenium Explores Bacterial Genes Inside Termite Guts to Understand How Wood is Broken Down and Converted to Energy 3Verenium Explores Bacterial Genes Inside Termite Guts to Understand How Wood is Broken Down and Converted to Energy 4Verenium Explores Bacterial Genes Inside Termite Guts to Understand How Wood is Broken Down and Converted to Energy 5SGX Pharmaceuticals to Present at Two Upcoming Investor Conferences 2
(Date:6/24/2015)... JOSE, Calif. , June 24, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... sensor to provide secure authentication for its latest ... recently reached more than 200 million shipments of ... with Sharp reinforces Synaptics, strength, scalability and leadership ...
(Date:6/23/2015)... RALEIGH, N.C. , June 23, 2015 /PRNewswire/ ... technology, today announced the results of a recent ... unmatched accuracy on the wrist during activity. In ... biometric technology was compared along with the Apple ... for accurately measuring heart rate during activity. The ...
(Date:6/17/2015)... , and HILDEN, Germany , June 17, ... ; Frankfurt Prime Standard: QIA) today launched new Investigator ® ... forensic laboratories in the United States . ... simultaneously analyze multiple key genomic markers (short tandem repeats or ... Quality Sensor to evaluate the quality of DNA in each ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5
... NASA,s space shuttle Discovery will make its swan song ... Boulder-built biomedical payload devices, including one to help scientists ... in the low gravity of space as a way ... The experiments will be carried aboard Discovery in sets ...
... Washington, DC (October 27, 2010) Recognizing the ... Collegiate Inventors Competition, a program of Invent Now, today ... in mice to facilitate drug testing and a way ... in this year,s competition. Alice Chen of the ...
... Move over, touchpad screens: New research funded in part ... possible to manipulate complex visual images on a computer screen ... Nature , found that when research subjects had their brains ... force the computer to display one of the images and ...
Cached Biology News:Swan song of space shuttle Discovery to carry 2 payloads built by CU-Boulder 2Swan song of space shuttle Discovery to carry 2 payloads built by CU-Boulder 3Winners announced in 2010 Collegiate Inventors Competition 2Winners announced in 2010 Collegiate Inventors Competition 3Winners announced in 2010 Collegiate Inventors Competition 4Winners announced in 2010 Collegiate Inventors Competition 5From touchpad to thought-pad? 2From touchpad to thought-pad? 3
... Antibody, Unconjugated Applications: ... dilution of 1/100. IP: Use at ... at an assay dependent dilution. Predicted ... in other applications. Optimal dilutions/concentrations ...
Kit containing MACS equipment and reagents for immunopurification of proteins....
Membrane Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
... Successful biomarker discovery projects require ... samples to distinguish clinically relevant data ... CiphergenExpress Data Manager is now available ... sample tracking and data flood inherent ...
Biology Products: